Navigation Links
Emphasys Medical to Present VENT Clinical Trial Data at ATS 2008
Date:5/12/2008

REDWOOD CITY, Calif., May 12 /PRNewswire/ -- Emphasys Medical Inc., today announced that one-year data from the VENT clinical trial of the company's Zephyr(R) Endobronchial Valve (EBV) will be presented at the International Conference of the American Thoracic Society (ATS) occurring May 16 to 21 in Toronto, Canada.

Sunday, May 18, 9:30-11:00 a.m. (ET), Metro Toronto Convention Centre, Room 801A

In the symposium, "Innovations in Emphysema Treatment: Lung Volume Reduction and Lung Volume Reduction Surgery," Zephyr related presentations include:

-- Frank Sciurba, M.D., University of Pittsburgh Medical Center, the

principal investigator of VENT, will present on the Durability of

Endobronchial Valve Effect on Lung Function at 6 and 12 Months.

-- Jonathan Goldin, M.D., Ph.D., University of California at Los Angeles,

the principal investigator of the VENT radiology core lab, will

present on Fissure Integrity As a Marker of Collateral Ventilation

Across Lung Lobes.

-- Jim Egan, M.D., Mater Misericordiae Hospital, Dublin, Ireland, will

present on the Treatment of Advanced Emphysema by Endoscopic Volume

Reduction.

-- John Travaline, M.D., Temple University, will present on the Efficacy

of Endobronchial Valves in the Treatment of Persistent Air Leaks.

Monday, May 19, 8:30 a.m., Metro Toronto Convention Centre, Room 715A

-- Charlie Strange, M.D., Medical University of South Carolina will

present on the relation of FEV1/FVC and Fissure Integrity in the VENT

Study.

Monday, May 19, 3:10 p.m., Metro Toronto Convention Centre, Hall G

-- Frank Sciurba, M.D., will present on Bronchoscopic Methods for

Palliation of Emphysema.

About the Zephyr Endobronchial Valve

The Zephyr EBV is a novel, minimally-invasive device intended to treat emphysema. The Zephyr EBV is designed to isolate diseased, overinflated portions of the lung and cause them to shrink thereby allowing healthier portions of the lung to function more normally.

The Zephyr EBV is CE marked and is commercially available in Europe and other international markets, including Australia, New Zealand, Hong Kong and Singapore. The Zephyr EBV is limited to investigational use in the United States. The company's Premarket Approval Application is currently under review by the U.S. Food and Drug Administration.

About Emphasys Medical

Emphasys Medical (http://www.emphasysmedical.com) is a medical technology company focused on developing and commercializing therapeutic devices for the treatment of patients with emphysema and other debilitating breathing disorders. Based in Redwood City, California, Emphasys Medical was incubated at The Foundry.


'/>"/>
SOURCE Emphasys Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Emphasys Medical Announces PMA Submission for Bronchial Valve Therapy
2. MSU engineering team designs innovative medical device
3. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
4. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
5. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
6. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
7. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
8. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
9. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
10. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
11. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... NY (PRWEB) , ... July 28, 2017 , ... ... asset protection and financial planning assistance to families and business owners in and ... Tournament to be held in honor of the Make-A-Wish Foundation. , The Make-A-Wish ...
(Date:7/27/2017)... ... July 27, 2017 , ... Dr. ... Board of Oral Implantology/Implant Dentistry (ABOI/ID). After successfully completing an extensive two-day examination ... of dental implants . Dr. Kimowitz and his partner Dr. Hal Kimowitz, ...
(Date:7/27/2017)... ... July 27, 2017 , ... TransPanel Volume 4 is ... This Final Cut Pro X exclusive features transitions that contain between 2 and 6 ... the transition using intuitive drop-down menus. TransPanel Volume 4 makes editing easy in Final ...
(Date:7/27/2017)... ... July 27, 2017 , ... GAFFEY ... internal promotion of Elrene Clinkscales to Vice President of Revenue Cycle Business Services ... reporting to Derek Morkel, chief executive officer (CEO). , Elrene has been with ...
(Date:7/27/2017)... Ga. (PRWEB) , ... July 27, 2017 , ... Team ... native Sam Brand to the men’s pro squad as a stagiaire for the remainder ... make his professional debut on July 31st at the Tour of Utah. , “Every ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... Aesthetics, a leading medical aesthetic clinic in Singapore ... skin conditions from the inside. The natural process of ... skin becomes more transparent due to the thinning of the epidermis. Over ... the sun contributes to aging skin, causing age spots and other ... ...
(Date:7/25/2017)... BARCELONA, Spain and CAMBRIDGE, Massachusetts ... SOM Biotech, specializing in repurposing drugs to treat rare nervous ... Therapeutics Inc. to clinically develop and market the drug SOM0226 ... reached, the drug achieved very promising results in a Phase ... A new office in the United ...
(Date:7/24/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) announced ... operating results on Monday, August 7, 2017 after market ... p.m. ET. Shareholders ... of the conference call by dialing 877-201-0168 or 647-788-4901 ... 15 minutes prior to the call. A live webcast ...
Breaking Medicine Technology: